about
sameAs
Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials.Nutraceuticals and headache: the biological basis.[How do sumatriptan and co. work? The action mechanisms of triptans].Valdecoxib for treatment of a single, acute, moderate to severe migraine headache.Why pharmacokinetic differences among oral triptans have little clinical importance: a comment.Dihydroergotamine and its metabolite, 8'-hydroxy-dihydroergotamine, as 5-HT1A receptor agonists in the rat brainInfrequent or non-response to oral sumatriptan does not predict response to other triptans--review of four trials.A pharmacogenomic evaluation of migraine therapy.Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine.A Neurologist's Guide to Acute Migraine Therapy in the Emergency Room.Migraine management: How do the adult and paediatric migraines differ?Pathways to the best fit of triptans for migraine patients.Early treatment in migraine: how strong is the current evidence?Randomized, controlled trial of telcagepant for the acute treatment of migraine.Meeting acute migraine treatment needs through novel treatment formulations.5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?Triptan nonresponders: do they exist and who are they?Drug safety and tolerability in prophylactic migraine treatment.Inhaled drug therapy development for the treatment of migraine.The influence of genetic constitution on migraine drug responses.MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine.A double-blind, randomized, placebo-controlled, single-dose study of the cyclooxygenase-2 inhibitor, GW406381, as a treatment for acute migraine.Evaluation of efficacy, tolerability, and treatment satisfaction with almotriptan in 3 consecutive migraine attacks. The migraine--satisfaction with treatment: reality with Almogran study.Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders.Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial.Consistent efficacy, tolerability, and high levels of satisfaction with almotriptan 12.5 mg when used to treat multiple migraine attacks in routine clinical practice.Negative predictors of clinical response to triptans in patients with migraine.Amitriptyline in the treatment of primary headaches.Triptans: low utilization and high turnover in the general population.Topiramate versus migraine: which is the cause of glaucomatous visual field defects?Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination.Overview of migraine treatment.Association of RAMP1 rs7590387 with the risk of migraine transformation into medication overuse headache.Polygenic risk score: use in migraine research.Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention--a randomized, double-blind, multicentre, placebo-controlled study.
P2860
Q33237366-6AD2342D-C0D2-4EE8-9EFC-2686E757176FQ34166931-36D924DD-D8AF-4654-94F0-093BDBC08A79Q34647941-26CE4A1B-AA87-495F-9164-883CC015AFF7Q34651032-016AB202-915B-40D9-8C70-FB031A4D0B9BQ34770884-71888CC8-0C43-4898-A787-7322A0B96DB6Q35045324-10344BCB-2348-4CA0-ABA5-8A711C091148Q36373560-6C75B12B-D4EE-4478-817C-2C18C4DB42A7Q36909258-850D5531-B60D-4F2F-AEAC-4CB3C7F6A0FEQ36947155-2616F01C-0ABB-4802-858F-65BCC6E924F4Q37080223-CE3DD147-C80D-4CBB-B458-373B3BF8AC97Q37098961-985B83C4-18DD-4A77-9926-732E406E5838Q37247869-B4DEE0DF-45E1-4551-992B-62D5A1EC6860Q37247872-E9116BA8-22EB-4775-BD4D-71CC8915B265Q37368387-F6AA4F98-70DA-48BB-8822-128622B5A12BQ37739586-842B0CA0-CB9E-471C-9A31-5F94CE503348Q37739587-FAD7C0D8-56EE-41FF-8CD8-52C0A4B4CFCAQ38096945-568C5591-3C01-44F8-AEE9-CE31272079E3Q38353242-A81E4CED-AADA-4E81-8E1F-095739661A72Q38896569-C2BBFF22-B130-4979-9D4F-A9F065EDA5B2Q38949801-9BE1AA68-EF2C-4448-92C2-4BE1A7884B1CQ39268172-0283B141-8992-4E53-9A94-0DFC73581B6FQ39322927-A7A97890-063C-41D5-A019-4D02E692408BQ39349941-77716BE2-3993-4FF9-82F8-ADA10B82D3CBQ39355111-2EF80FB6-7683-40CF-9538-6B40C9B34F2EQ39365280-E7D6E98A-EC7A-4393-A6E3-8EFE48FB01EFQ39365816-B60F71E0-1CA1-4898-8730-807507A2BC71Q39720265-A1B9809A-249E-4E7A-B577-BEFC4B80C331Q43265634-A34F4353-6F41-4DBE-928C-22C09C32BCE8Q43280720-7EA81D7E-8BED-4F74-8AD0-FF27A7F2E2E5Q44187298-A2476DB5-BEAA-48AD-B52D-21BB966FEA3FQ45131483-8D8E5577-2D76-42C0-B2FC-AED961A51B17Q46098987-B862A4E6-32D2-40B7-A996-108FCDBFCD67Q48226245-DE5BC854-ECEA-4898-B71D-C37BF6984DA9Q55004438-CF916645-4F1F-4F55-8819-D8317BD461AEQ55041322-BF47887B-3948-475B-BE35-638C59D6C6B5
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Advances in pharmacological treatment of migraine
@ast
Advances in pharmacological treatment of migraine
@en
Advances in pharmacological treatment of migraine
@nl
type
label
Advances in pharmacological treatment of migraine
@ast
Advances in pharmacological treatment of migraine
@en
Advances in pharmacological treatment of migraine
@nl
prefLabel
Advances in pharmacological treatment of migraine
@ast
Advances in pharmacological treatment of migraine
@en
Advances in pharmacological treatment of migraine
@nl
P2860
P1476
Advances in pharmacological treatment of migraine
@en
P2093
V Limmroth
P2860
P304
P356
10.1517/13543784.10.10.1831
P407
P577
2001-10-01T00:00:00Z